drugset / Trial / NCT03699033
Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-10-01
- Completion
- 2020-10-01
Outcome
Outcome not reported
Stopped: “No patients available”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | Paclitaxel | Small molecule | 45 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | — |